LYEL vs TECH · rev $61.0K vs P/E 65, rev $1.22B
Lyell Immunopharma Inc (LYEL) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported LYEL revenue for 2024-12-31 was $61.0K. Net income was -$343.0M. Revenue was down 53.1% from 2023-12-31 to 2024-12-31. LYEL currently screens at market cap $143.5M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
LYEL currently screens at market cap $143.5M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the LYEL and TECH stock pages for the full models.
Not investment advice.